Literature DB >> 32445908

Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles.

Qiuying Liao1, Ivan C H Lam2, Hinson H S Lin1, Leon T L Wan1, Jason C K Lo1, Waiting Tai3, Philip C L Kwok3, Jenny K W Lam4.   

Abstract

Spray freeze drying is a particle engineering technique that allows the production of porous particles of low density with excellent aerosol performance for inhalation. There are a number of operating parameters that can be manipulated in order to optimise the powder properties. In this study, a two-fluid nozzle was used to prepare spray freeze dried formulation of voriconazole, a triazole antifungal agent for the treatment of pulmonary aspergillosis. A full factorial design approach was adopted to explore the effects of drug concentration, atomisation gas flow rate and primary drying temperature. The aerosol performance of the spray freeze dried powder was evaluated using the next generation impactor (NGI) operated with different inhaler devices and flow rates. The results showed that the primary drying temperature played an important role in determining the aerosol properties of the powder. In general, the higher the primary drying temperature, the lower the emitted fraction (EF) and the higher the fine particle fraction (FPF). Formulations that contained the highest voriconazole concentration (80% w/w) and prepared at a high primary drying temperature (-10 °C) exhibited the best aerosol performance under different experimental conditions. The high concentration of the hydrophobic voriconazole reduced surface energy and cohesion, hence better powder dispersibility. The powders produced with higher primary drying temperature had a smaller particle size after dispersion and improved aerosol property, possibly due to the faster sublimation rate in the freeze-drying step that led to the formation of less aggregating or more fragile particles. Moreover, Breezhaler®, which has a low intrinsic resistance, was able to generate the best aerosol performance of the spray freeze dried voriconazole powders in terms of FPF.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol performance; Antifungal agent; Factorial design; Freeze drying; Inhalation; Pulmonary delivery; Spray freeze drying

Mesh:

Substances:

Year:  2020        PMID: 32445908     DOI: 10.1016/j.ijpharm.2020.119444

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

2.  Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl-β-Cyclodextrin as Excipient.

Authors:  Jason C K Lo; Harry W Pan; Jenny K W Lam
Journal:  Pharmaceutics       Date:  2021-04-24       Impact factor: 6.321

3.  Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.

Authors:  Han Cong Seow; Qiuying Liao; Andy T Y Lau; Susan W S Leung; Shuofeng Yuan; Jenny K W Lam
Journal:  Int J Pharm       Date:  2022-03-28       Impact factor: 6.510

4.  Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.

Authors:  Si Nga Wong; Jingwen Weng; Ignatius Ip; Ruipeng Chen; Richard Lakerveld; Richard Telford; Nicholas Blagden; Ian J Scowen; Shing Fung Chow
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

5.  Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy.

Authors:  Zitong Shao; Waiting Tai; Yingshan Qiu; Rico C H Man; Qiuying Liao; Michael Y T Chow; Philip C L Kwok; Jenny K W Lam
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.